Clinical trial directly comparing iTrack Advance to our closest competitor, Omni. It should reveal that iTrack Advance is substantially superior to Omni and is therefore the best-in-class canaloplasty option. The release of results will therefore most likely be a major catalyst event, as it should significantly boost sales.
Link to Study: Multicenter Glaucoma Study Investigating Standalone Canaloplasty - Full Text View - ClinicalTrials.gov
- Forums
- ASX - By Stock
- EYE
- Ann: Glaucoma Sales update
Ann: Glaucoma Sales update, page-10
-
-
- There are more pages in this discussion • 13 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
LU7
Discover the strong preliminary feasibility of the Bécancour Lithium Refinery, showcasing resilience in a low pricing environment and a strategic plan to capitalize on future price recoveries
NEWS
Breakthrough programs slash healthcare events, driving a significant A$1.8M+ annual revenue boost
Add EYE (ASX) to my watchlist
(20min delay)
|
|||||
Last
18.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $41.23M |
Open | High | Low | Value | Volume |
19.0¢ | 19.0¢ | 18.0¢ | $24.11K | 132.1K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
4 | 137086 | 17.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
18.5¢ | 30000 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
2 | 70000 | 0.175 |
5 | 102280 | 0.170 |
4 | 114241 | 0.165 |
9 | 297300 | 0.160 |
1 | 10000 | 0.155 |
Price($) | Vol. | No. |
---|---|---|
0.185 | 30000 | 1 |
0.190 | 120204 | 4 |
0.200 | 93423 | 2 |
0.205 | 15050 | 1 |
0.215 | 204291 | 4 |
Last trade - 14.41pm 04/10/2024 (20 minute delay) ? |
Featured News
NEWS
Breakthrough programs slash healthcare events, driving a significant A$1.8M+ annual revenue boost
LU7
Discover the strong preliminary feasibility of the Bécancour Lithium Refinery, showcasing resilience in a low pricing environment and a strategic plan to capitalize on future price recoveries
EYE (ASX) Chart |